Fibronectin based scaffold domain proteins that bind IL-23

Details for Australian Patent Application No. 2011218243 (hide)

Owner Bristol-Myers Squibb Company

Inventors Bush, Alex; Dasgupta, Ruchira; Engle, Linda; Schneeweis, Lumelle

Agent A J Park

Pub. Number AU-A-2011218243

PCT Pub. Number WO2011/103105

Priority 61/305,566 18.02.10 US; 61/330,706 03.05.10 US

Filing date 16 February 2011

Wipo publication date 25 August 2011

International Classifications

C07K 14/78 Peptides having more than 20 amino acids

A61K 38/39 Medicinal preparations containing peptides - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)

C12N 15/10 Mutation or genetic engineering - Processes for the isolation, preparation or purification of DNA or RNA

C40B 30/04 Methods of screening libraries - by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

A61K 38/00 Medicinal preparations containing peptides

Event Publications

4 October 2012 PCT application entered the National Phase

  PCT publication WO2011/103105 Priority application(s): WO2011/103105

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011218250-Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit

2011218237-Pulse dynamic logic gates with MUX-D scan functionality